Zoetis Inc.
Every calculator, already run for ZTS
Open the full toolkit →You have the numbers on ZTS. Get the argument.
A written report on which of these readings actually decide the outcome for Zoetis Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering ZTSAnalyst Price Target Disagreement for Zoetis Inc.
Wall Street's bull case implies +117% from the current price; the bear case implies +12%. A 105% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ZTS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care di…
ZTS — frequently asked
Is ZTS a buy right now?
Wall Street's consensus rating on Zoetis Inc. is Buy across 17 analysts, with a mean price target of $96.00 (+34% vs. the current $71.43). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ZTS overvalued?
ZTS trades at 11.7x trailing earnings, against a DCF fair value of $147 per share. The current price implies -3% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ZTS's next earnings date?
Zoetis Inc. is next scheduled to report earnings around Nov 5, 2026. A full ZTS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Zoetis Inc.?
Analysts covering Zoetis Inc. (ZTS) range from a bear-case target of $80.00 to a bull-case high of $155.00, with a mean consensus target of $96.00 across 14 analysts. The spread of $75.00 (105% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Zoetis Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Zoetis Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ZTS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Zoetis Inc., in minutes. 3 free reports included with every account — no credit card required.